Journal article
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
- Abstract:
-
Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, 1.9MB)
-
- Publisher copy:
- 10.2217/fon-2020-1048
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
Sierra Oncology Ltd. (Sponsor)
More from this funder
Bibliographic Details
- Publisher:
- Future Medicine Publisher's website
- Journal:
- Future Oncology Journal website
- Volume:
- 17
- Issue:
- 12
- Pages:
- 1449-1458
- Publication date:
- 2021-01-11
- Acceptance date:
- 2020-12-14
- DOI:
- EISSN:
-
1744-8301
- ISSN:
-
1479-6694
- Pmid:
-
33423550
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1156862
- Local pid:
- pubs:1156862
- Deposit date:
- 2021-01-21
Terms of use
- Copyright holder:
- Sierra Oncology
- Copyright date:
- 2021
- Rights statement:
- ©2021 Sierra Oncology, Vancouver, BC, Canada. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
If you are the owner of this record, you can report an update to it here: Report update to this record